Vaibhavi Peshattiwar

Vaibhavi Peshattiwar

Auto-generated profile, based on publicly available information

Vaibhavi Peshattiwar

Department of Neurology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, 43620

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
SDSagar Dhoble
Sagar Dhoble
VGVinod Ghodake
Vinod Ghodake
VPVaibhavi Peshattiwar
Vaibhavi Peshattiwar
VPVandana Patravale
Vandana Patravale

21 November 2024 in Translation: The University of Toledo Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
CSCaroline Swain
Caroline Swain
VPVaibhavi Peshattiwar
Vaibhavi Peshattiwar
KLKhoi Le
Khoi Le
INIsabel Nester
Isabel Nester
KVKala Venkiteswaran
Kala Venkiteswaran
TSThyagarajan Subramanian
Thyagarajan Subramanian
Translation: The University of Toledo Journal of Medical Sciences is the online journal launched by the University of Toledo. Manuscripts will be considered on the understanding that they report original work and are not under consideration for publication by any other journal. The journal publishes original articles reporting experimental results of basic or clinical research, case reports, and reviews. The journal uses a single blind peer review system and each manuscript, based on the results presented in its original submission, will be evaluated by two student reviewers and one faculty reviewer. This process will provide an opportunity for medical students, graduate students, residents, fellows and faculty to publish research observation in a timely manner.

6 November 2026 in Journal of Parkinson’s Disease
Verified
Journal Article
Open access
CSCaroline C Swain
Caroline C Swain
VPVaibhavi V Peshattiwar
Vaibhavi V Peshattiwar
Dipesh Pokharel, PhDDipesh Pokharel, PhD
Dipesh Pokharel, PhD
KLKhoi Le
Khoi Le
IKIsabel Kennedy
Isabel Kennedy
KVKala Venkiteswaran
Kala Venkiteswaran
Increasing evidence supports the existence of a distinct body-first subtype of Parkinson's disease (PD), in which the initial site of pathology is in the gut. Animal models that recapitulate the body-first subtype of PD are needed. We tested the hypothesis that non-motor features of the body-first subtype of PD are recapitulated in the paraquat and lectin (P + L) rat model of PD, a model that has previously demonstrated the pathological motor progression of this subtype of PD. Then, we tested whether oral squalamine, a gastrointestinal prokinetic that has been shown to reduce formation of pathological α-synuclein, could prevent pathology, motor, and non-motor findings. Rats (n = 93) were orally gavaged for seven days with paraquat (1 mg/kg) and lectin (0.05%) in 1% sucrose solution. A subset of rats (n = 37) were given 30 days of squalamine (20 mg/kg) in their drinking water immediately following P + L treatment. Rats were tested for parkinsonian motor deficits, gastrointestinal dysmotility, sleep abnormalities, and cognitive deficits. Rats were euthanized and their brains processed for phospho-S 129 -α-synuclein pathology and neurodegeneration. We show that the P + L rat model recapitulates non-motor features and pathology of gastrointestinal dysmotility and sleep abnormalities seen in the body-first subtype of PD. We show that oral squalamine prevents motor deficits, gastrointestinal dysmotility, and sleep abnormalities, and diminishes phospho-S 129 -α-synuclein pathology and neurodegeneration in the nigrostriatal pathway. We show that the P + L rat model recapitulates many features of the body-first subtype of PD and provides pre-clinical evidence for the use of squalamine to mitigate progression in the body-first subtype of PD.

21 October 2021 in Research Square
Verified
Preprint
Open access
PDF file
VPVaibhavi Peshattiwar
Vaibhavi Peshattiwar
SMSuraj Muke
Suraj Muke
AKAakruti Kaikini
Aakruti Kaikini
SBSneha Bagle
Sneha Bagle
VDVikas Dighe
Vikas Dighe
SSSadhana Sathaye
Sadhana Sathaye
Parkinson’s disease (PD) ranks as second most prevalent neurodegenerative disorder but is devoid of neuroprotective treatment. Approaches with disease modifying ability with symptomatic relief has become an utmost necessity. Further multifactorial nature of PD presents challenges for efficacy evaluation of any potential test compound. The stated study makes an attempt to address these issues by employing a rotenone induced PD model involving a bilateral intranigral stereotactic rotenone injection for evaluation of the neuroprotective efficacy of Daidzein (DZ). DZ a soy isoflavone, is known for its various health benefits viz. immunomodulation, cardiovascular effects etc. In this study, animals after intranigral rotenone (12 μg) injection, were treated with DZ at a dose of 5, 10 and 20 mg/kg for 30 days. The neurobehavioural evaluation comprised of Rota-rod, Open field and Barnes maze test. The biochemical analysis constituting oxidative stress (Reduced glutathione, superoxide dismutase, catalase and lipid peroxidation), inflammation (TNF-α), mitochondrial alteration (complex I activity and biogenesis) was conducted on mid-brain tissue after 30 days of treatment. The SN and striatum was also subjected to immunohistochemical analysis (IHC) for TH positive neurons and Glial Fibrillary Acidic Protein. The analysis revealed significant improvement by daidzein in motor co-ordination and attenuation in cognitive deficits due to rotenone. The biochemical assessment exhibited significant decrement in oxidative stress as well as inflammation. DZ treatment also prevented complex I inhibition and promoted mitochondrial biogenesis eventually contributing to the neuroprotection apparent in IHC. Thus, the results strongly corroborate the neuroprotective potential of DZ against rotenone induced model of PD.

19 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
VPVaibhavi Peshattiwar
Vaibhavi Peshattiwar
CSCaroline Swain
Caroline Swain
Dipesh Pokharel, PhDDipesh Pokharel, PhD
Dipesh Pokharel, PhD
KLKhoi Le
Khoi Le
IKIsabel Kennedy
Isabel Kennedy
TSThyagarajan Subramanian
Thyagarajan Subramanian
The recent growing evidence support the existence of two subtypes of Parkinson’s disease (PD), a body first and brain first subtype owing to variability in the disease site of onset as well as disease progression. Animal models which could replicate the specific differences of these subtypes are important to explore the pathophysiology as well as to evaluate novel treatment options. Here, we describe an animal model of body first PD subtype developed using repeated low dose exposure of environmental neurotoxin Paraquat (P) and Lectin (L) to characterize its PD-like manifestations. We administered P+L (P+L, p.o.) daily to rats for 90 days. These animals underwent motor and non-motor behavioral tests at various time intervals. After 21 weeks, post-mortem histopathological analysis was performed to assess neurodegeneration. Onset of motor deficits initiated unilaterally from week 4 of P+L followed by gradual progression towards bilateral symptoms that were levodopa responsive. This model also replicates non motor features including cognitive deficits in tests like Novel Object Recognition Test and Y maze as well as sleep abnormalities. The histopathology showed nigrostriatal dopaminergic degeneration and proteinase K resistant S129 alpha-synucleinopathy both in the gut and the brain. The replication of both progressive motor and non-motor features in this rat model corroborates body first subtype of PD therefore making it an attractive option for testing neuroprotective experimental therapeutics and avenue to understand pathophysiological mechanisms.

11 December 2025 in Exploration of Neuroprotective Therapy
Verified
Journal Article
Open access
SBSneha Bagle
Sneha Bagle
SMSuraj Muke
Suraj Muke
VPVaibhavi Peshattiwar
Vaibhavi Peshattiwar
AKAakruti Kaikini
Aakruti Kaikini
DDDR VIKAS DIGHE
DR VIKAS DIGHE
SSSadhana Sathaye
Sadhana Sathaye
Aim: Alzheimer’s disease (AD) devastates learning and memory, the defining faculties of the human species. Extracellular amyloid beta (Aβ) deposits and intracellular hyperphosphorylated tau are hallmarks of AD pathology. The exact cause of the disease remains unknown, but a lot of data support AD to be a multifactorial disease. Given the central roles of oxidative stress and neuroinflammation in AD pathogenesis, apocynin, a potent antioxidant and anti-inflammatory agent, was selected for investigation. Apocynin is an aromatic ketone, a naturally occurring methoxy-substituted catechol known to possess numerous biological activities, namely anti-oxidant, anti-inflammatory, etc. The present study assessed apocynin’s potential against an Aβ1–42-induced sporadic AD rat model. Methods: In the present study, Wistar rats were subjected to intrahippocampal administration of 200 µmol/L of Aβ1–42 peptide in right hemisphere. Further were treated with apocynin 50, 150, and 300 mg/kg per orally for 28 days. The study examined the neurobehavioral aspects using the Barnes Maze test (BMT). Hippocampus was examined for the antioxidant (SOD, GSH, catalase, and LPO), inflammatory (TNF-α) parameters, RAGE, caspase-3, PGC-1α expression, and IHC analysis for Aβ load, adult hippocampal neurogenesis markers (BDNF, Ki67, DCX, NeuN), at the end of 28 days. Results: Apocynin administration demonstrated significant improvement in cognitive functions, diminished oxidative stress and inflammatory response triggered by Aβ administration. Apocynin additionally instigated adult hippocampal neurogenesis and triggered mitochondrial biogenesis. Conclusions: These primary results strongly advocate apocynin’s nootropic, neurotrophic and neuroprotective potential in an Aβ induced neurotoxicity in rats.